Lacosamide Sandoz

Lacosamide, the active ingredient in Lacosamide Sandoz, is an anticonvulsant presented as an oral dosage form for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy, often as adjunctive therapy. GNH USA supplies Lacosamide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that targets neuronal hyperexcitability in focal seizure disorders. - Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Adjunctive therapy for epilepsy: improves overall seizure control in patients already on antiepileptic regimens. - Focal epilepsy: provides additional seizure reduction as part of a combination treatment plan.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac arrhythmia or PR‑interval prolongation - Atrial fibrillation - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Hepatic dysfunction - Blood dyscrasias including agranulocytosis

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and assess liver enzymes regularly. - Cardiac conduction abnormalities: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. - Concomitant CNS depressants: may increase sedation, requiring dose adjustments. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma concentrations. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): increase risk of cardiac conduction delay.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, lamotrigine): may enhance adverse effect profile. - Central nervous system depressants (e.g., benzodiazepines, alcohol): can potentiate sedation. - Renally excreted agents (e.g., trimethoprim): monitor renal function and drug levels.